Michael Graves - 21 Dec 2023 Form 4 Insider Report for EAGLE PHARMACEUTICALS, INC. (EGRX)

Reporting relationship: Interim Executive Chair & PEO, Director
Issuer ticker: EGRX
Reported as of: 21 Dec 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Dec 2023, 19:00:19 UTC
Prior SEC filing: 31 Oct 2023
Source filing: View source filing
Reporting owner signature: /s/ Michael Graves

Key filing fact

Michael Graves filed Form 4 for EAGLE PHARMACEUTICALS, INC. (EGRX) on 22 Dec 2023.

Key facts

This page summarizes Michael Graves's Form 4 filing for EAGLE PHARMACEUTICALS, INC. (EGRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 Dec 2023, 19:00.

Change

Previous filing in this sequence was filed on 31 Oct 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EGRX transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +293,000
Change %
Price: $0.000000
Shares after: 293,000
Date: 21 Dec 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 293,000
Exercise price: $5.01
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option was granted in connection with the Reporting Person's appointment as Interim Executive Chairman and Interim Principal Executive Officer. The option vests in 12 equal monthly installments commencing on November 27, 2023, subject to the Reporting Person's continuous service with the Issuer as of the vesting date.